Associations between epicardial, visceral and subcutaneous adipose tissue with diastolic function in men with and without HIV.

BACKGROUND: People with HIV (PWH) are at greater risk for diastolic dysfunction (DD) compared to persons without HIV (PWOH). An increase in visceral adipose tissue (AT) is common among PWH and greater visceral AT is associated with DD among PWOH. We investigated associations of visceral AT, subcutaneous AT and other fat depots with subclinical DD among men with and without HIV (MWH/MWOH). DESIGN: Cross-sectional analysis of MWH and MWOH in the Multicenter AIDS Cohort Study (MACS). METHODS: Participants underwent echocardiography for DD assessment and CT scanning including subcutaneous, visceral, epicardial, and liver adiposity measurements. DD was defined by Characterizing Heart Function on Antiretroviral Therapy criteria. Odds for DD with each measure of adiposity were estimated using multivariable logistic regression. RESULTS: Among 403 participants (median age 57, 55% white, median BMI 26 kg/m2), 25% met criteria for DD and 59% MWH (82% undetectable plasma HIV RNA). Greater epicardial AT area was associated with higher odds of DD (odds ratio:1.54 per SD;95%CI:1.15-2.05) when adjusted for demographics, HIV serostatus, and cardiovascular risk factors. This association did not differ by HIV serostatus and persisted when excluding MWH who were not virally suppressed. Less subcutaneous AT was associated with a higher odds of DD. Other adipose depots were not associated with DD. CONCLUSIONS: Greater epicardial AT and less subcutaneous AT were associated with DD, regardless of HIV serostatus and viral suppression. Greater epicardial AT and less subcutaneous AT observed among PWH may contribute to risk for heart failure with preserved ejection fraction in this population.

Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.

BACKGROUND AND OBJECTIVES: Osteoprotegerin (OPG), a cytokine that regulates bone resorption, has been implicated in the process of vascular calcification and stiffness. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum OPG was measured in 351 participants with chronic kidney disease (CKD) from one site of the Chronic Renal Insufficiency Cohort Study. Cortical bone mineral content (BMC) was measured by quantitative computed tomography in the tibia. Multivariable linear regression was used to test the association between serum OPG and traditional cardiovascular risk factors, measures of abnormal bone and mineral metabolism, and pulse wave velocity. RESULTS: Higher serum OPG levels were associated with older age, female gender, greater systolic BP, lower estimated GFR, and lower serum albumin. OPG was not associated with measures of abnormal bone or mineral metabolism including serum phosphorus, albumin-corrected serum calcium, intact parathyroid hormone, bone-specific alkaline phosphatase, or cortical BMC. Among 226 participants with concurrent aortic pulse wave velocity measurements, increasing tertiles of serum OPG were associated with higher aortic pulse wave velocity after adjustment for demographics, traditional vascular risk factors, and nontraditional risk factors such as estimated GFR, albuminuria, serum phosphate, corrected serum calcium, presence of secondary hyperparathyroidism, serum albumin, and C-reactive protein or after additional adjustment for cortical BMC in a subset (n = 161). CONCLUSIONS: These data support a strong relationship between serum OPG and arterial stiffness independent of many potential confounders including traditional cardiovascular risk factors, abnormal bone and mineral metabolism, and inflammation.